BRIEF-Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases

Reuters
08 Nov 2024

Nov 8 (Reuters) - Allovir Inc :

* ALLOVIR AND KALARIS THERAPEUTICS ANNOUNCE AGREEMENT FOR TRANSFORMATIONAL MERGER TO CREATE COMPANY FOCUSED ON DISEASES OF THE RETINA

* ALLOVIR INC - TO ACQUIRE 100% OF KALARIS EQUITY INTEREST

* ALLOVIR INC - STOCKHOLDERS TO OWN 25.05% OF COMBINED COMPANY POST-MERGER

* ALLOVIR INC - COMBINED COMPANY TO BE LED BY KALARIS CEO ANDREW OXTOBY

* ALLOVIR INC - COMBINED COMPANY TO OPERATE AS KALARIS THERAPEUTICS, INC. AND TRADE AS KLRS

* ALLOVIR INC - TH103 PHASE 1 CLINICAL TRIAL DATA EXPECTED IN Q3 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10